#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    SAPHO syndrome Biliary cancer metastatic Neuroblastoma Cushing's syndrome Cytomegalovirus infection Asthma Immunodeficiency Squamous cell carcinoma of head and neck Narcolepsy Pneumonia Metabolic disorder Osteosarcoma metastatic Cutaneous T-cell lymphoma refractory Basal cell naevus syndrome Acute leukaemia More trials…

    Learn about Rare Diseases

    Angiosarcoma metastatic – Treatment Wiskott-Aldrich syndrome – Diagnostics Hairy cell leukaemia – Basic Information Mantle cell lymphoma stage II – Life with Disease CADASIL – Diagnostics Mantle cell lymphoma stage II Epidermolysis bullosa – Basic Information Progressive multifocal leukoencephalopathy – Basic Information Congenital nephrogenic diabetes insipidus Gaucher’s disease type I More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Betahistine Dihydrochloride Dapagliflozin Fentanyl Citrate Arachis Hypogaea Flour Namodenoson Encorafenib Marstacimab Baloxavir Marboxil Nepafenac Tamoxifen Citalopram Donepezil ULTEVURSEN Givinostat Dotatate Tisotumab Vedotin Methotrexate Sodium Cytarabine Doxorubicin Hydrochloride Xenon (129Xe) More therapies…

    Learn about Your Condition

    Medication overuse headache Acute lymphocytic leukaemia Gastric cancer stage IV Bipolar I disorder Vaginal haemorrhage Osteosarcoma recurrent Amyotrophic lateral sclerosis Pancreatitis acute Foetal growth restriction Varices oesophageal Diabetic neuropathy Peripheral artery thrombosis Upper limb fracture Acarodermatitis Pulmonary fibrosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Non-small cell lung cancer

  • Study on Continued Ceritinib Treatment for Patients with ALK Positive Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Ceritinib
    Belgium Bulgaria France Germany Italy Poland

  • Study of Davutamig (REGN5093) for Patients with Advanced Non-Small Cell Lung Cancer with MET Alterations

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Davutamig
    France

  • Study Comparing Lorlatinib and Crizotinib for Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage IV
    • Non-small cell lung cancer
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Lorlatinib
    Belgium Czechia France Germany Italy The Netherlands +2

  • Study of Nivolumab and Relatlimab for Patients with Resectable Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Relatlimab
    • Nivolumab
    Belgium Germany The Netherlands

  • Study on the Effectiveness and Safety of Osimertinib for Patients with Stage IB-IIIA Non-Small Cell Lung Cancer After Tumor Removal

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage I
    • Non-small cell lung cancer stage II
    • Non-small cell lung cancer stage III
    Investigated Drugs:
    • Osimertinib
    Belgium France Germany Italy Poland Spain +1

  • Study on the Safety of Osimertinib with Radiation for Patients with Stage IV EGFR-Mutation Positive Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Lung neoplasm malignant
    • Non-small cell lung cancer stage IV
    • Non-small cell lung cancer
    Investigated Drugs:
    • Osimertinib
    Germany
Previous Page
1 … 40 41 42 43 44 … 54
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!